These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21709712)

  • 1. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer.
    Fujiwara T
    Acta Med Okayama; 2011 Jun; 65(3):151-62. PubMed ID: 21709712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.
    Fujiwara T; Shirakawa Y; Kagawa S
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):525-32. PubMed ID: 21504319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Urata Y; Tanaka N
    Curr Cancer Drug Targets; 2007 Mar; 7(2):191-201. PubMed ID: 17346111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents.
    Fujiwara T; Urata Y; Tanaka N
    Front Biosci; 2008 Jan; 13():1881-6. PubMed ID: 17981675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.
    Kojima T; Watanabe Y; Hashimoto Y; Kuroda S; Yamasaki Y; Yano S; Ouchi M; Tazawa H; Uno F; Kagawa S; Kyo S; Mizuguchi H; Urata Y; Tanaka N; Fujiwara T
    Ann Surg; 2010 Jun; 251(6):1079-86. PubMed ID: 20485131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase-specific replication-selective virotherapy for human cancer.
    Kawashima T; Kagawa S; Kobayashi N; Shirakiya Y; Umeoka T; Teraishi F; Taki M; Kyo S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):285-92. PubMed ID: 14734481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidisciplinary oncolytic virotherapy for gastrointestinal cancer.
    Fujiwara T
    Ann Gastroenterol Surg; 2019 Jul; 3(4):396-404. PubMed ID: 31346579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
    Fujiwara T; Kagawa S; Tazawa H
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.
    Fujiwara T; Tanaka N
    Uirusu; 2008 Jun; 58(1):11-8. PubMed ID: 19122384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oncolytic virotherapy for human solid tumors].
    Fujiwara T
    Gan To Kagaku Ryoho; 2009 May; 36(5):703-9. PubMed ID: 19461167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.
    Kuroda S; Fujiwara T; Shirakawa Y; Yamasaki Y; Yano S; Uno F; Tazawa H; Hashimoto Y; Watanabe Y; Noma K; Urata Y; Kagawa S; Fujiwara T
    Cancer Res; 2010 Nov; 70(22):9339-48. PubMed ID: 21045143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase-specific virotheranostics for human head and neck cancer.
    Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
    Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice.
    Lin WH; Yeh SH; Yang WJ; Yeh KH; Fujiwara T; Nii A; Chang SS; Chen PJ
    Int J Cancer; 2013 Mar; 132(6):1451-62. PubMed ID: 22886913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.
    Hashimoto Y; Tazawa H; Teraishi F; Kojima T; Watanabe Y; Uno F; Yano S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2012; 7(6):e39292. PubMed ID: 22720091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
    Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
    Wang H; Wei F; Li H; Ji X; Li S; Chen X
    Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.